Unveiling the Key Fundamentals of Kenvue (KVUE)

By Scott Lee • Saturday, February 22 15:11 • Permanent Link

Shares of Specialty Chemicals company Kenvue jumped 4.2% today. With many investors piling into KVUE without a second thought, it may be a good idea to take a closer look at the stock. Here are some quick facts to get you started:

Kenvue has moved 23.1% over the last year, and the S&P 500 logged a change of 18.6%
KVUE has an average analyst rating of buy and is 0.21% away from its mean target price of $23.27 per share
Its trailing earnings per share (EPS) is $0.54
Kenvue has a trailing 12 month Price to Earnings (P/E) ratio of 43.2 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $1.22 and its forward P/E ratio is 19.1
The company has a Price to Book (P/B) ratio of 4.2 in contrast to the S&P 500's average ratio of 4.74
Kenvue is part of the Consumer Discretionary sector, which has an average P/E ratio of 22.6 and an average P/B of 3.19
KVUE has reported YOY quarterly earnings growth of -12.2% and gross profit margins of 0.6%
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.